kynurenine pathway

March 17, 2026

The role of the kynurenine pathway in conditioned place aversion induced by synthetic cannabinoid CP-55940

Abstract Background: The therapeutic potential of cannabinoids is increasingly recognized; however, their use is often associated with adverse effects, such…

January 25, 2024

Dysfunction in endocannabinoids, palmitoylethanolamide, and degradation of tryptophan into kynurenine in individuals with depressive symptoms

Abstract Background: The endocannabinoid (eCB) system and the serotonin (5-HT) are both implicated in the severity of the depression. 5-HT…

November 22, 2022

Alterations in rat prefrontal cortex kynurenic acid levels are involved in the enduring cognitive dysfunctions induced by tetrahydrocannabinol exposure during the adolescence

Abstract Introduction: Cannabis abuse during adolescence is a risk factor for cognitive impairments in psychiatric disorders later in life. To…

September 28, 2022

Gram-Scale Preparation of Cannflavin A from Hemp (Cannabis sativa L.) and Its Inhibitory Effect on Tryptophan Catabolism Enzyme Kynurenine-3-Monooxygenase

Abstract Simple Summary: Kynurenine-3-monooxygenase (KMO) is an enzyme in the neurotoxic branch of the kynurenine pathway (KP) and is a…

May 31, 2021

Pro-Inflammatory Cytokines: Potential Links between the Endocannabinoid System and the Kynurenine Pathway in Depression

Abstract Substance use/abuse is one of the main causes of depressive symptoms. Cannabis and synthetic cannabinoids in particular gained significant…

October 15, 2019

Kynurenines and the Endocannabinoid System in Schizophrenia: Common Points and Potential Interactions

Abstract Schizophrenia, which affects around 1% of the world’s population, has been described as a complex set of symptoms triggered…